Trifluridine-Tipiracil (TAGS) — 3L+ gastric/GEJ
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-TRIFLURIDINE-TIPIRACIL |
|---|
| ID | REG-TRIFLURIDINE-TIPIRACIL-GASTRIC |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-GASTRIC-2024 SRC-NCCN-GASTRIC-2025 |
Notes
TAGS trial (Shitara 2018): 3L+ gastric/GEJ adenocarcinoma after ≥2 prior regimens — TAS-102 vs placebo mOS 5.7 vs 3.6 mo (HR 0.69), PFS 2.0 vs 1.8 mo. NCCN cat 1 for 3L+ gastric. Distinct mechanism from prior fluoropyrimidine exposure (TS-independent thymidine analog incorporation) — active in 5-FU-refractory disease. Main toxicity is myelosuppression (neutropenia ~38%). Hand-foot reactions notably less than fluoropyrimidine.
Used By
Indication
IND-GASTRIC-METASTATIC-3L-TAS102- IND-GASTRIC-METASTATIC-3L-TAS102